Monopar Therapeutics Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1000 Skokie Boulevard Wilmette IL United States of America 60091
- IPO Date
- Dec 19, 2019
- CIK
- 0001645469
- Website
- monopartx.com
- Similar Companies
- Business
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Company News
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
3 Momentum Stocks Soaring Into 2025 and Beyond
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder